Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Senti Biosciences Holdings, Inc. (SNTI)

Senti Biosciences divests operating unit in merger, issues CVRs up to $60 million

Negative Impact 5 of 5 m&a Written later

On October 21, 2026, Senti Biosciences completed a merger in which it divested its entire ownership interest in its Midco and Opco subsidiaries to Parent, which acquired substantially all of the company's existing business and pipeline. Shareholders receive contingent value rights that may pay up to $60.0 million on SENTI-202 milestones, but the filing says these payments are highly speculative and may never be paid, and that the company may not be able to maintain operations as early as the fourth quarter of 2026.

Key points

  • Merger closed October 21, 2026; the company received no cash at closing and divested Midco and Opco.
  • CVRs may pay up to $60.0 million in total: $10.0 million on BLA filing or acceptance, $20.0 million on FDA approval, and $30.0 million on cumulative net sales above $200.0 million.
  • The company sold 7,309,941 shares at $0.342 per share to CPIF II-7 Limited for about $2.5 million.
  • The company estimates a loss on disposal of $6.652 million and says it may not be able to maintain operations as early as Q4 2026.

The filing

CompanySenti Biosciences Holdings, Inc. (SNTI)
Form8-K, current report
Filed with the SECOct 26, 2026, 4:17 PM ET
Accession number0001140361-26-040772

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.01 Acquisition or Disposition Completed3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.